Safety of Vraylar vs. Other Antipsychotics Drugs Compared in New Drug Safety Monitor from Advera Health Analytics

Share Article

Comparative safety research review covers Abilify (Bristol-Meyers), Fanapt (Novartis), INVEGA (J&J), Risperdal (J&J), Risperdal Consta (Janssen)

News Image
Our goal is to make drug safety transparent for payers, physicians and patients. The Drug Safety Monitor consistently offers MCOs actionable drug safety information, often well before FDA.

The Advera Health Analytics, Inc. analyst team published a new Drug Safety Monitor, “Schizophrenia and Bipolar Disorder: Safety Comparison of Vraylar vs. 'Other Antipsychotics' Drug Class.”

Actionable Intelligence – The recently approved atypical antipsychotic Vraylar appears to be a safer alternative to Risperdal with a similar risk profile to Abilify, for the treatment of schizophrenia and bipolar disorder. While all three drugs carry a 'Boxed Warning' for increased risk of death in elderly patients with dementia-related psychosis, Risperdal has the longest list (177) of labeled adverse reactions with numerous serious non-labeled RxSignals (drug-induced liver injury, posterior reversible encephalopathy syndrome and hepatitis cholestatic). Advera Health’s comparative analysis of the 'other antipsychotics' drug class points towards Invega and Risperdal Consta (Risperdal's long-acting injectable) as riskier options, while Abilify appears to be the safest of the class.

Drugs Covered – Abilify, Fanapt, INVEGA, Risperdal, Risperdal Consta, Vraylar

Indications Covered – Bipolar Disorder, Schizophrenia

Classes Covered – Other antipsychotics

Mechanisms of Action Covered – Dopamine Agonists, Dopamine Antagonists, Serotonin Agonists, Serotonin Antagonists

The DSM helps Managed Care Organizations (MCOs) incorporate safety data and comparative safety research into P&T decisions, daily pharmacy workflows, and drug price negotiations. Advera Health offers the DSM at no charge to qualified MCOs to enable health plans, payers, systems, and hospitals to incorporate drug safety insight and analysis into their decision making process. The DSM is also available at no charge to healthcare media organizations to serve as an independent, unbiased resource and research tool for their pharma industry reporting.

Advera Health President Brian Overstreet commented, “Our goal is to make drug safety transparent for payers, physicians and patients. The Drug Safety Monitor consistently offers MCOs actionable drug safety information, often well before FDA.”

To obtain more information on the above DSM or to receive a complimentary subscription to the Advera Health Drug Safety Monitor click here: http://info.adverahealth.com/subscribe-drug-safety-monitor-center

ABOUT ADVERA HEALTH ANALYTICS
Advera Health Analytics is a health informatics company that improves patient safety and reduces systemic healthcare costs through the comprehensive analysis of real world outcomes data. Advera Health Analytics makes these data accessible, actionable, and predictable. For more information visit adverahealth.com – and connect with us on LinkedIn, Facebook and Twitter.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty

Sharon Miller
Visit website